← All trials
NCT04858659
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2021
- Primary completion
- Mar 15, 2022
- Completion date
- Mar 15, 2022
- First posted
- Apr 26, 2021
- Last posted
- Sep 22, 2021
- Enrollment
- 354
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PMG Pharm Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.